They assured that they are currently working closely with experts and regulators to evaluate the data.
In a letter to the New England Journal of Medicine, scientists at Johnson & Johnson’s vaccine division Janssen stated that there is not enough evidence that the company’s Covid-19 vaccine causes rare blood clots, and they are ” To evaluate the data with experts and regulatory agencies, we support the open communication of this information with healthcare professionals and the public.”
They wrote: “Currently, there is insufficient evidence to establish a causal relationship between these events and the Ad26.COV2.S vaccine.”
The U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration recommend that the vaccine be suspended due to 6 rare cases of blood clots in the brain and a small amount of platelets (called platelets).
Scientists explained that Johnson & Johnson had only one case of this rare disease before, so the final stage of vaccine testing was suspended. In this case, it determined that “there is no clear cause and effect”, and the Safety Oversight Committee agreed to continue the trial.
Since the vaccine was licensed for use in the United States, in the company’s surveillance, the company has found 6 cases of this situation among the 7.2 million vaccines it manages. This case occurred 7 to 14 days after vaccination.
Scientists say that this rare blood clot (cerebral venous sinus thrombosis) occurred within the expected range, but it should be noted that the incidence of these low platelet clots is unknown and is considered “extremely low” by the FDA and CDC. .
Although these blood clots occurred after the use of Johnson & Johnson and AstraZeneca vaccines, and the vaccine used a similar platform, namely adenovirus vectors, scientists believe that the platforms are different and may have different effects. AstraZeneca is from chimpanzees and Johnson & Johnson is from humans.
The letter read: “More evidence is needed to clarify the observations of thrombotic thrombocytopenia in people receiving the Covid-19 vaccine.”